CivaTech Oncology (“CivaTech”) completed a Series F equity raise to fund clinical experience and studies for its primary offerings and to scale R&D and manufacturing capabilities.

CivaTech, located in Research Triangle Park, NC, United States, develops and provides unique, patented polymer-based low-dose-rate (LDR) brachytherapy devices. The Company’s devices are designed to be delivered in a single procedure, with no subsequent interventions required. In doing so, the Company’s innovations minimize distress and inconvenience while maximizing quality of life and improving life expectancy.

EC M&A acted as financial advisor to CivaTech and its shareholders on this transaction.